Skip to content
by Legal Desire
19 July 2024

Latham & Watkins Advises Invetx in Acquisition by Dechra Pharmaceuticals

Advising firms

Deal team

22 lawyers named
LawyerFirmSeniorityPracticeOffice
Kristen Grannis Lead Latham & Watkins LLP Partner corporate Boston
Spencer Ricks Lead Latham & Watkins LLP Partner corporate Boston
Gloria Ring Lead Latham & Watkins LLP Counsel corporate Boston
Andrew Rondeau Latham & Watkins LLP Associate corporate Not stated
Christine Kalpin Latham & Watkins LLP Associate corporate Not stated
Josh Friedman Latham & Watkins LLP Partner benefits and compensation Boston
Tessa Young Latham & Watkins LLP Associate benefits and compensation Not stated
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Dennis Poehland Latham & Watkins LLP Associate tax Not stated
Josh Holian Latham & Watkins LLP Partner antitrust Bay Area
Ian Conner Latham & Watkins LLP Partner antitrust Washington, D.C.
Patrick English Latham & Watkins LLP Partner antitrust Washington, D.C.
Ehson Kashfipour Latham & Watkins LLP Associate antitrust Not stated
Sarah Gagan Latham & Watkins LLP Partner intellectual property Boston
Eliot Choy Latham & Watkins LLP Counsel intellectual property New York
Arun Mohan Latham & Watkins LLP Associate intellectual property Not stated
Heather Deixler Latham & Watkins LLP Partner data privacy Bay Area
Mitch Bennett Latham & Watkins LLP Associate data privacy Not stated
Elizabeth Richards Latham & Watkins LLP Partner FDA regulatory Washington, D.C.
Meryl Bartlett Latham & Watkins LLP Associate FDA regulatory Not stated
Eveline Van Keymeulen Latham & Watkins LLP Partner EU regulatory Brussels
Jeanne Fabre Latham & Watkins LLP Associate EU regulatory Not stated

19 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 520m (US$520 million)
What the figure measures
Total transaction value
Client
Invetx, Inc.Sell-side
Counterparties
Dechra Pharmaceuticals Limited (Buy-side)